Age-related macular degeneration (AMD)
Conditions
Interventions
HAWK/HARRIER Group :Intravitreal injection of 0.05ml of Conbercept eye injection under the 3+T&E regimen of the HAWK/HARRIER trial standards.
PULSAR Group :Intravitreal injection of 0.05ml of Conbercept eye injection under the 3+T&E regimen of the PULSAR trial standards.
Sponsors
Huai'an First People's Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged >=50 years and =300µm, meeting the diagnostic criteria for neurodegenerative age-related macular degeneration (nAMD). 2. Completed a minimum of 6months of follow-up. 3. Completed at least three loading doses of 10mg/ml Conbercept, followed by a standardized treatment regimen (e.g., fixed, treat-and-extend, or PRN). 4. Availability of complete baseline data.
Exclusion criteria
Exclusion criteria: 1. In the study eye, presence of fundus diseases other than neovascular age-related macular degeneration (nAMD), including choroidal neovascularization (CNV) due to etiologies such as polypoidal choroidal vasculopathy (PCV), pathologic myopia with CNV, macular hole, epiretinal membrane, diabetic retinopathy, retinal vein occlusion, proliferative vitreoretinopathy, etc. 2. Known allergy or hypersensitivity to mydriatic drugs, local anesthetics, or contrast agents. 3. History of intraocular surgery, ocular trauma, or fundus laser photocoagulation. 4. Uncontrolled glaucoma in the study eye or evidence of extraocular/periocular infection or inflammation in either eye (including infectious blepharitis, keratitis, scleritis, or conjunctivitis). 5. History of idiopathic or autoimmune uveitis in the study eye. 6. Poor compliance with diagnosis or treatment. 7. History of intraocular corticosteroid or anti-VEGF injections, photodynamic therapy (PDT), or other intraocular treatments within 3 months prior to enrollment. 8. During the observation period, cataract surgery, vitreoretinal surgery, or intravitreal corticosteroid injections were performed. 9. Significant opacity of the refractive medium, impairing image formation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with prolonged treatment intervals and frequency of injections between the two groups at week 24; | — |
Secondary
| Measure | Time frame |
|---|---|
| Variation of central subfield thickness;Incidence of serious adverse reactions;Proportion of patients achieving >=5 letter improvements in BCVA at 24 weeks; | — |
Countries
China
Contacts
Public ContactLi Chaopeng
Huai'an First People's Hospital
Outcome results
None listed